Treatment Characteristics
| Characteristic | All patients (n = 90) | PET-positive (n = 42) | PET-negative (n = 48) |
| ADT with stop before last follow-up/duration (mo) | 23/5 (2–23) | 23/5 (2–23) | — |
| Ongoing ADT at last follow-up (n) | 3 | 2 | 1 |
| No ADT (n) | 64 | 17 | 47 |
| Median PSA before radiation therapy (ng/mL) | 0.44 (0.11–6.24) | 0.68 (0.3–6.24) | 0.34 (0.11–3.24) |
| Radiation therapy* (Gy) | |||
| Former prostate | 66 (59.4–70.2) | ||
| Lymphatic pathways | 50.4 (45–50.4) | ||
| PET-positive local recurrence | 70.0 (67.2–72) | ||
| PET-positive lymph node | 60.76 (54–66) |
↵* Radiation therapy technique for all patients was volume-modulated arc therapy/intensity-modulated radiotherapy and image-guided radiotherapy.
Data in parentheses are ranges.